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Summary
Objectives: A comparison of clinical and laboratory features, diagnostic methods, drug treat-
ment, and outcomes for patients hospitalized with malaria by Plasmodium species.
Methods: Records of 521 patients hospitalized during the four and half-year study period were
analyzed.
Results: Infections were caused by Plasmodium vivax (51.8%), Plasmodium falciparum (46.5%), P.
vivax plus P. falciparum (1.3%), and Plasmodiummalariae (0.4%). Vomiting (odds ratio (OR) = 1.86,
p = 0.001) and abdominal pain (OR = 1.60, p = 0.024) occurredmore frequently in patients infected
with P. falciparum compared to P. vivax; this was also the case for hepatomegaly, splenomegaly and
jaundice. Lowhemoglobin levels were common butwere significantly lowerwith P. falciparum, and
creatinine levels were significantly higher with P. falciparum. Treatment regimens consisted of
single drug therapy (61.5%), appropriate combination therapy (15.8%), and inappropriate combina-
tion therapy (22.7%). Antimalarials given alone included chloroquine (38.7%), quinine (19%) and
doxycycline (1.5%). The overall mortality was 1.7% (n = 9) and nearly 56% of patients developed
disease complications, most commonly thrombocytopenia (36.4%), anemia (23.4%), and thrombo-
cytopenia plus anemia (32.7%).
Conclusions: Despite resistance, chloroquine was prescribed in patients with malaria requiring
hospitalization. We found a high proportion of single antimalarial drug use as well as inappropriate
combination therapy (22.7%), and inadequate use of primaquine terminal prophylaxis. Physicians
need to be acquainted with malaria treatment guidelines in an endemic zone.
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Each year, malaria results in approximately 300—500 million
clinical cases and 1—3 million deaths worldwide,1 especiallyPublished by Elsevier Ltd. All rights reserved.
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Figure 1 Annual number of malaria cases at the Aga Khan
University Hospital by year, January 1997—July 2001.in tropical developing countries.2,3 Malaria mortality can
exceed 30% among patients with severe complicated
malaria, even in modern intensive care units.4 Malaria is
endemic in Pakistan, with the majority of cases caused by
Plasmodium vivax, although recently there has been an
alarming shift to infection caused by Plasmodium falci-
parum, especially in the southern Punjab, Baluchistan
and Sindh provinces.5—9
There is a paucity of literature comparing the clinical
outcomes of hospitalized patients with P. vivax and P.
falciparum infection in Pakistan. We sought to compare
the clinical, hematological, and other laboratory features,
diagnostic techniques, drug treatments, and outcomes
for infections caused by these two malaria species seen
in an academic tertiary care setting in Karachi, Pakistan,
and to determine the appropriateness of prescribed drug
therapy.
Materials and methods
Study setting
The Aga Khan University Hospital (AKUH) is a 650-bed private
tertiary care hospital centrally located in Karachi, Pakistan
(current population estimate, 17 million persons), and
serving the inhabitants of the city and surrounding Sindh
Province, and elsewhere in Pakistan. Two-thirds of patients
receiving care at the hospital are from lower-to-middle
socioeconomic classes.
Subjects
Subjects selected for study were patients admitted to the
AKUHwith a primary diagnosis of malaria during the four and
a half-year period from January 1997 through July 2001.
Cases were identified using the hospital’s computerized,
diagnosis-based Hospital Information Management System
and searching for the keywords, ‘malaria’ and ‘Plasmo-
dium’. Cases were only included if there was a definite
laboratory-confirmed diagnosis of malaria. Medical records
were retrospectively reviewed and the extracted data
included information on: age, sex, presenting signs and
symptoms, previous exposure to malaria, co-morbidities,
initial laboratory results, and parasitological examinations
during hospitalization, drug treatment regimens, complica-
tions, and parasitological and clinical outcome at the time of
hospital discharge. Analysis of the appropriateness or inap-
propriateness of antimalarial drug therapy was based uponTable 1 Malaria cases admitted to the Aga Khan University Hospit
2001
Gender Species
P. vivax P. falciparum
Men 163 141
Women 107 101
Total 270 242
a P. vivax plus P. falciparum.treatment recommendations published during the study
period.10
Data analysis
Clinical data were analyzed using SPSS version 13 software.
Comparisons were made between P. vivax and P. falciparum
in terms of age, sex, temporal variations, presenting symp-
toms, physical findings, laboratory test results, parasitologi-
cal examination, management, and complications.
Proportions were compared using the Chi-square test or
Fisher’s exact test, where appropriate, and means were
compared using the Student’s t-test.
Results
Demographics
Five hundred and twenty-one cases of malaria were identi-
fied and included in this analysis. Annual numbers of total
malaria cases and cases categorized by species are shown in
Figure 1. The mean patient age was 34.9 years (range, 1 to 89
years). Cases of malaria according to Plasmodium species are
shown in Table 1. There were 270 (51.8%) cases of P. vivax
infection, 242 (46.5%) cases of P. falciparum, seven (1.3%)
cases of mixed infection (P. vivax plus P. falciparum), and two
(0.4%) cases caused by Plasmodium malariae. The male:fe-
male ratio was 1.5:1. The temporal distribution of malaria
cases, with annual occurrences by month, is shown in
Figure 2. Similar patterns were observed across the study
years 1997 to 2001, with maximum peaks in July and August
coinciding with the monsoon season in Pakistan, and with
lowest rates of infection during January of each year.al according to Plasmodium species, January 1997 through July
P. malariae Mixeda Total
0 5 309
2 2 212
2 7 521
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Figure 2 Temporal distribution of malaria cases at the Aga
Khan University Hospital, January 1997—July 2001.Presenting symptoms and signs
Comparisons of presenting symptoms and clinical findings
according to infecting parasite species are shown in Table 2.
Fever was the most common presenting symptom, seen in 97%
of cases regardless of species, followed by chills (62.7%) and
vomiting (54.1%). Vomiting occurred more frequently in
patients infected with P. falciparum compared to P. vivax
(62.0% vs. 46.7%, respectively; odds ratio (OR) = 1.86,
p = 0.001). Plasmodium falciparum-infected patients also
reported abdominal pain more frequently (28.5% vs. 20.0%;
OR = 1.60, p = 0.024). There were no other significant differ-
ences among presenting symptoms according to the infecting
species.Hepatomegaly, splenomegaly, and jaundicewere seen
more frequently among patients with falciparum malaria
compared to those infected with P. vivax (Table 2).Table 2 Comparison of presenting signs and symptoms among ca
Feature P. falciparum
(n = 242) %
P. vivax
(n = 270) %
Symptom
Fever 96.3 97.0
Chills 64.5 60.7
Diarrhea 14.5 16.3
Headache 24.4 20.4
Seizures 2.9 4.8
Myalgias 11.2 9.3
Arthralgias 2.1 1.9
Vomiting 62.0 46.7
Abdominal pain 28.5 20.0
Sweating 17.4 14.8
Anorexia 3.7 1.5
Sign
Lung findings 20.3 14.8
Hepatomegaly 28.1 11.9
Splenomegaly 22.3 12.2
Neck stiffness 1.7 0.4
Jaundice 20.3 4.1Diagnosis
Techniques used for diagnosis of malaria included peripheral
film (thick or thin smear) examination, quantitative buffy
coat examination (no longer used at AKUH), polymerase
chain reaction (PCR), and immunochromatography (ICT)
(Table 3). Thin blood smear was the most common method
employed in diagnosing both P. vivax and P. falciparum
species (89%).
Laboratory indices
Comparisons of mean laboratory values according to infect-
ing parasite species are shown in Table 4. Low hemoglobin
levels were present in both study cohorts but were signifi-
cantly lower in those infected with P. falciparum, with a
mean value of 10.2 mg/dl vs. 11.2 mg/dl for subjects with P.
vivax infection ( p = 0.001). Serum creatinine levels were
significantly higher in subjects with falciparum malaria
(1.5 mg/dl vs. 1.1 mg/dl; p = 0.013).
Treatment
Comparisons of antimalarial drug treatment according to
parasite species are shown in Table 5. Antimicrobial agents
prescribed included chloroquine, quinine, doxycycline,
amodiaquine, pyrimethamine—sulfadoxine, clindamycin,
artemether, halofantrine, and primaquine. Treatment regi-
mens consisted of single drug therapy (61.5%), appropriate
combination therapy (15.8%), and inappropriate combina-
tion therapy (22.7%). Antimalarial agents given alone
included chloroquine (38.7%), quinine (19%) and doxycycline
(1.5%). Chloroquine plus primaquine (1.1%), quinine plus
doxycycline (13.9%), quinine plus clindamycin (0.6%), and
quinine plus doxycycline (0.2%) were considered to be
appropriate rational combination regimens. Inappropriateses of malaria according to Plasmodium species
OR 95% CI p Value
0.79 0.30—2.08 0.634
1.17 0.82—1.68 0.385
0.87 0.54—1.41 0.566
1.26 0.83—1.91 0.276
0.59 0.23—1.50 0.262
1.23 0.69—2.19 0.478
1.12 0.32—3.91 0.999
1.86 1.31—2.65 0.001
1.60 1.06—2.40 0.024
1.21 0.75—1.94 0.434
2.57 0.78—8.45 0.108
1.46 0.92—2.31 0.105
2.91 1.83—4.62 0.001
2.06 1.29—3.31 0.002
4.52 0.50—40.73 0.194
5.98 3.03—11.8 <0.001
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Table 3 Diagnostic techniques used for malaria detection according to Plasmodium species
Method P. falciparum
(n = 242) %
P. vivax
(n = 270) %
OR 95% CI p Value
Thick smear 1.2 3.0 0.41 0.11—1.57 0.179
Thin smear 86.8 90.4 0.70 0.40—1.21 0.200
QBC 14.1 11.5 1.26 0.75—2.12 0.384
PCR 0.4 1.1 0.37 0.04—3.57 0.626
ICT 0.8 0.4 2.24 0.20—24.88 0.605
QBC, quantitative buffy coat; PCR, polymerase chain reaction; ICT, immunochromatographic technique.
Table 4 Comparison of laboratory indices among patients with malaria according to Plasmodium species
Laboratory indices Species p Value
P. falciparum P. vivax
No. Mean No. Mean
White blood cells (per mm3) 226 7312 243 7622 0.185
Serum glucose (mg/dl) 121 139.6 125 128.6 0.185
Hemoglobin (g/dl) 238 10.2 256 11.2 0.001
Platelet count (per mm3) 228 103.5 238 91.0 0.114
Serum bicarbonate (mEq/l) 133 21.6 150 21.3 0.537
Serum creatinine (mg/dl) 190 1.5 190 1.1 0.013combinations included chloroquine plus quinine (4.8%),
chloroquine plus quinine plus doxycycline (2.3%), chloro-
quine plus amodiaquine (0.6%), quinine plus primaquine
(0.6%), and others (14.4%). Artemether was given to only
1.2% of the patients in combinationwith other antimalarials.
Primaquine was appropriately administered as prophylaxis
to prevent relapse in only 6.2% of cases infected with P.
vivax.
Complications and outcome
The overall mortality for study subjects was 1.7% (n = 9).
Mortality among patients with falciparum malaria was 2.0%,
and for patients with P. vivax infection it was 1.5%. Nearly
56% of patients developed disease complications, which
included thrombocytopenia (36.4%), anemia (23.4%), throm-
bocytopenia plus anemia (32.7%), jaundice (1.4%), pneumo-
nia (0.7%), thrombocytopenia and/or anemia with otherTable 5 Comparison of drug treatment among patients with ma
Drugs Species
P. falciparum n (%)
Chloroquine 60 (22.6)
Quinine 185 (82)
Amodiaquine 5 (83)
Doxycycline 91 (88)
Pyrimethamine—sulfadoxine —
Clindamycin 8 (89)
Artemether 3 (100)
Halofantrine 7 (54)
Primaquine 1 (5)
a P. vivax plus P. falciparum.complications (4.1%), and other complications (1.4%)
(Table 6).
Discussion
From the 1960s to the early 1990s, P. vivax was the pre-
dominant malaria species in Pakistan, however, the incidence
of P. falciparum has increased considerably over the last
decade.7,11—13 During our study period (1997—2001), infec-
tion caused by these two species was seen in comparable
frequency. Cases of malaria had a typical summer monsoon
seasonal peak, but with transmission occurring throughout
the year.14 Inter-annual climate variability has been reported
to be an important determinant of epidemics, and climate
forecasts can be used as early warning of changes of risk in
epidemic-prone regions.15
In the individual patient, although it is not possible to
determine the infecting species of Plasmodium on the basis oflaria according to Plasmodium species
P. vivax n (%) Mixeda n (%)
205 (77) 1 (0.4)
36 (16) 5 (2)
1 (17) —
7 (7) 5 (5)
6 (100) —
1 (11) —
— —
6 (46) —
17 (90) 1 (5)
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Table 6 Complications of malaria in patients at the Aga
Khan University Hospital, January 1997 through July 2001
Complication No. %
Absent 230 44.1
Present 291 55.9
Thrombocytopenia 106 20.3
Anemia 68 13.1
Thrombocytopenia plus anemia 95 18.2
Thrombocytopenia plus
anemia plus other
12 2.3
Jaundice 4 0.8
Pneumonia 2 0.4
Acute renal failure 1 0.2signs and symptoms alone, the presence of vomiting
( p < 0.001) appears to occur more commonly in falciparum
malaria, and this feature has been reported previously.16
Similarly, the presence of hepatomegaly, splenomegaly,
and jaundice may also be more associated with P. falciparum
infection compared to disease caused by P. vivax. While acute
renal failure was seen in only one of our patients, the mean
serum creatinine level was significantly higher in the P.
falciparum cohort. Severe oliguric renal failure may occur
in malaria from a combination of factors including hypovo-
lemia, microvascular blockade, and hemolysis.17 Diagnostic
algorithms for malaria that include presenting signs and
symptoms and lab findings may help guide empiric drug
treatment and may be useful in endemic settings in order
to help reduce disease morbidity and mortality.
Thin peripheral blood smear was the most common diag-
nostic method in our series, for all species. Immunochroma-
tography was performed in only a few patients when it was
introduced in our hospital in 2001, although recent studies
show that this technique can be a useful rapid diagnostic
method, especially for the identification of mixed malaria
infection.17 The fluorescent quantitative buffy coat techni-
que, positive in 12.7% of our cohort, is available for malaria
diagnosis and has a sensitivity and specificity of 88—98% and
58—90%, respectively, compared to conventional micro-
scopy.18 However, this test is not widely used due to its cost
and lack of ability to differentiate between species of
malaria. PCR techniques based upon the detection of nucleic
acid sequences (DNA or mRNA) specific to Plasmodium spe-
cies have the ability to detect parasitemia levels as low as 5
parasites/ml. PCR was used in a limited number of our cohort
subjects because the technology was new and expensive at
the time of the study. However, rapid PCR-based methods
have become routine in our clinical laboratory, especially
when blood microscopy is negative, and the sensitivity and
specificity of PCR approaches 100%.19—21
Timely diagnosis and institution of rational and effective
empiric chemotherapy are both important prognostic vari-
ables in malaria.22 Despite the high incidence of chloroquine
resistance in Pakistan at the time of this study,23 chloroquine
was still inappropriately used in almost a quarter of all
patients infected with P. falciparum. Quinine was prescribed
more commonly in subjects with falciparum malaria, but its
recommended combination with doxycycline or clindamycin
was not optimal. An artemisinin agent was used in only a verylimited number of our cohort because of the historical setting
and/or the cost. Moreover, combination antimalarial ther-
apy, even when prescribed, was considered rational and
appropriate in only about 15% of our subjects. In our study,
death occurred in a small numbers of patients, thereby
limiting statistical analysis of potential drug therapy associa-
tions. Therapeutic outcomes and local and national drug
resistance patterns must be considered when treatment
guidelines are formulated.
There are several limitations of our study. Patients
admitted to our private, academic teaching hospital may
not have been representative of the general population of
Karachi or the surrounding catchment area. Bias may have
been introduced due tomissing or incomplete documentation
of case histories in the medical records. Parasitemia was
assessed at the time of admission only and could have biased
results. Primaquine prophylaxis was appropriately used in
only 6.2% of our P. vivax cohort; while this could have had an
impact on the incidence of relapse, treatment failures were
not assessed in this study.
In conclusion, despite the occurrence of chloroquine
resistance in Pakistan, physicians persist in inappropriately
prescribing chloroquine for patients with malaria requiring
hospitalization. We found a high incidence of less-than-
recommended single antimalarial drug use (61.5%), as well
as inappropriate combination therapy (22.7%), and inade-
quate use of primaquine terminal prophylaxis. Enhanced
educational efforts must continue to promulgate the use
of artemisinin-containing combination regimens in global
regions where drug-resistant malaria is a significant problem.
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